Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mireia Mele
Observed names:
M. Lo Mele,
Mireia Melé
Institutions:
Institut de Recerca Biomèdica Catalunya Sud,
Hospital Universitari Sant Joan de Reus
Observed institutions:
University of Padua,
Institut de Recerca Biomèdica Catalunya Sud,
Azienda Ospedale - Università Padova,
Hospital Universitari Sant Joan de Reus
ORCID:
0009-0007-3798-5965
Observed ORCID:
0009-0007-3798-5965
OpenAlex ID:
A5065412889
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
2025
·
Eva Ciruelos
, Tomás Pascual
, et al.
·
Clinical Cancer Research
·
2
Data from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
2026
·
Eva Ciruelos
, Tomás Pascual
, et al.
Supplementary Data 1 from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
2026
·
Eva Ciruelos
, Tomás Pascual
, et al.
Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study
2026
·
Bàrbara Roig
, Sara Fernández-Castillejo
, et al.
·
Scientific Reports
PDF
A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study
2022
·
F. Miglietta
, M. Ragazzi
, et al.
·
European Journal of Cancer
Show more works
View as search
Works count:
5
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type